Evidence map›Paper›PMID 34482456›Full record

ReviewJournal of neurology2022

Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders.

Hesham Abboud, Andrea Salazar-Camelo, Naveen George, Sarah M Planchon, Marcelo Matiello, Maureen A Mealy, Andrew Goodman, On-behalf of the Guthy-Jackson Foundation NMO International Clinical Consortium

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Area postrema syndrome and painful tonic spasms as initial manifestations of Neuromyelitis optica spectrum disorder in a 72-year-old female: a case report.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Article
  6. Immune-Mediated Myelopathies.Continuum (Minneapolis, Minn.) · 2024
    Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Hesham AbboudMultiple Sclerosis and Neuroimmunology Program, Parkinson's and Movement Disorders Center, University Hospitals of Cleveland, Case Western Reserve University, Bolwell, 5th floor, 11100 Euclid Avenue, Cleveland, OH, 44106, USA. Hesham.abboud@uhhospitals.org.ORCID http://orcid.org/0000-0001-5346-8254
Andrea Salazar-Camelo *Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Naveen George *Multiple Sclerosis and Neuroimmunology Program, Parkinson's and Movement Disorders Center, University Hospitals of Cleveland, Case Western Reserve University, Bolwell, 5th floor, 11100 Euclid Avenue, Cleveland, OH, 44106, USA.
Sarah M PlanchonThe Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH, USA.
Marcelo MatielloNeurology Department, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Maureen A MealyDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Andrew GoodmanNeuroimmunology Division, Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA.
On-behalf of the Guthy-Jackson Foundation NMO International Clinical Consortium
Cleveland Clinic · USJohns Hopkins University · USUniversity Hospitals of Cleveland · USHarvard University · USUniversity of Rochester Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuromyelitis optica spectrum disorders (NMOSD) are a group of autoimmune inflammatory conditions that primarily target the optic nerves, spinal cord, brainstem, and occasionally the cerebrum. NMOSD is characterized by recurrent attacks of visual, motor, and/or sensory dysfunction that often result in severe neurological deficits. In recent years, there has been a significant progress in relapse treatment and prevention but the residual disability per attack remains high. Although symptomatic and restorative research has been limited in NMOSD, some therapeutic approaches can be inferred from published case series and evidence from multiple sclerosis literature. In this review, we will discuss established and emerging therapeutic options for symptomatic treatment and restoration of function in NMOSD. We highlight NMOSD-specific considerations and identify potential areas for future research. The review covers pharmacologic, non-pharmacologic, and neuromodulatory approaches to neuropathic pain, tonic spasms, muscle tone abnormalities, sphincter dysfunction, motor and visual impairment, fatigue, sleep disorders, and neuropsychological symptoms. In addition, we briefly discuss remyelinating agents and mesenchymal stem cell transplantation in NMOSD.

Indexed as

Multiple SclerosisNeuromyelitis OpticaBrain StemHumansOptic NerveSpinal CordMesenchymal stem cellsNeuromyelitis opticaNeuropathic painNMONMOSDRemyelinationSymptomaticTonic spasms

Identifiers

PMID34482456
PMCPMC8940781
OpenAlexW3198316871

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.